Oncotag

What Oncotag does

Oncotag is a Brazilian precision oncology company that translates academic genetic research into clinical diagnostic tests for cancer prognosis and treatment guidance. Founded in 2013 and based in Nova Lima in the Belo Horizonte metropolitan area of Minas Gerais, the company operates with a stated team of 8 PhD-level scientists drawn from genetics, cell biology, immunology, computer science, bioinformatics, and clinical oncology. Co-founder Letícia Braga serves as CEO and coordinates the Translational Research Laboratory at partner institution Instituto Mário Penna.

The company's core offering is two proprietary multigene expression panels: OvarianTag®, a prognostic test for ovarian cancer patients, and the ElasTag Panel, used for women with triple-negative breast cancer and ovarian cancer. Both tests apply qRT-PCR (quantitative Reverse Transcription Polymerase Chain Reaction) to analyze tumor gene expression from paraffin block samples. Proprietary AI/ML algorithms — including C4.5 decision trees, Support Vector Machines, neural networks, and deep learning classifiers — convert the molecular profile into a clinical report predicting patient benefit from platinum-based chemotherapy, recurrence risk within 1 year, and survival probability. Oncotag claims this is the first multigene expression test developed in Brazil for evaluating response to platinum-based chemotherapy, and the company holds 5 deposited patents and registered trademarks for both product brands.

Oncotag's revenue model is one-time diagnostic testing service fees, with pricing not publicly disclosed and a 15-business-day turnaround time per test. Distribution is sales-led and strictly domestic (Brazil), executed through direct B2B partnerships with healthcare institutions — including Instituto Mário Penna, Complexo Hospitalar São Francisco, and Ipsemg — as well as physician-ordered testing via clinical oncologists. Revenue is undisclosed. The company has been supported by accelerator/grant funding from BiotechTown, Google for Startups, FAPEMIG, CNPq, Bio-Minas Brasil, Mubius Womentech Ventures, and FCJ Venture Builder, with no institutional venture rounds of significant size disclosed. Customer concentration is narrow both in customer count and geography.

Name

Oncotag

Legal name

Oncotag

Website

https://oncotag.com.br

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

1–10 employees

Short description

Oncotag is a Brazilian precision oncology company that develops AI-powered multigene expression panels (ElasTag and OvarianTag®) using qRT-PCR technology to predict platinum-based chemotherapy benefit and recurrence risk for ovarian and triple-negative breast cancer patients, serving healthcare institutions and oncologists in Brazil.

Ownership category

akta.pro rank

Product category

Genetic Diagnostic Testing Services

NAICS

Medical Laboratories (621511)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)

akta.pro secondary industry

Oncology Pathways & Precision Medicine Decision Support (HLACAGAH)

Keywords

• Molecular diagnostics
• Genetic testing
• Precision oncology
• Cancer genomics
• Pharmacogenetics

Headquarters

HQ city

Nova Lima

HQ country

Brazil

HQ region

Latin America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Genetic Diagnostic Testing Services: Oncotag generates revenue through providing genetic testing services to healthcare providers and patients. The company offers specialized multi-gene expression panels (ElasTag and OvarianTag) that analyze tumor samples to guide oncology treatment decisions. Testing is performed on tumor tissue samples (paraffin blocks) with results delivered within 15 business days.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Oncotag is a Brazilian precision oncology laboratory that performs genetic diagnostic testing on tumor tissue samples (paraffin blocks) using qRT-PCR multi-gene expression panels combined with proprietary AI/ML algorithms. The laboratory delivers clinical reports (within 15 business days) that predict a patient's likelihood of benefiting from platinum-based chemotherapy and assess ovarian cancer recurrence risk. Its flagship products are the OvarianTag® prognostic test for ovarian cancer and the ElasTag Panel for women with triple-negative breast cancer and ovarian cancer.

Product overview

Oncotag is a precision oncology company specializing in translational and pharmacogenetic research. The company offers two main genetic testing products: OvarianTag® for ovarian cancer prognosis and the ElasTag Panel for triple-negative breast and ovarian cancer patients. Both products use qRT-PCR technology to analyze multigene expression panels, with AI algorithms generating medical reports predicting platinum chemotherapy benefit and cancer recurrence risk. The company was founded in 2013 based on 12 years of research and brings basic research to clinical practice.

Differentiator

Problem solved

Functional benefit

Products and services

• OvarianTag® A genetic prognostic test for ovarian cancer patients using qRT-PCR to analyze selected gene panels from tumor samples, with AI algorithms predicting patient survival probability, disease recurrence risk within 1 year, and likelihood of benefiting from platinum-based chemotherapy. Aimed at oncologists and gynecologic oncology practices treating ovarian cancer patients.
• ElasTag Panel Multi-gene expression panel developed for women with triple-negative breast cancer and ovarian cancer. Analyzes tumor gene expression profiles from paraffin block samples using qRT-PCR and AI to predict benefit from platinum-based chemotherapy, supporting personalized oncology treatment decisions. Targeted at oncologists managing TNBC and ovarian cancer patients.
• Precision Oncology / Translational Pharmacogenetics Services Translational research and pharmacogenetic analysis services connecting basic research to clinical application in precision oncology. Delivers molecular profiling and treatment personalization based on individual tumor genetics for healthcare institutions, research partners, and clinical oncologists.

Quantifiable outcome

• First multigene expression test for platinum-based chemotherapy response in Brazil
• +1 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature4 records

Partnerships

Five partnerships are on record, tiered core and supporting.

• Instituto Mário PennacoreStrategic or Co-development PartnerInstituto Mário Penna is a key partner where Oncotag's Translational Research Laboratory is coordinated. This partnership enables the translation of basic research into clinical applications and provides institutional infrastructure for operations.
• Google for StartupssupportingGTM or Marketing PartnerGoogle for Startups partnership providing technology resources, cloud infrastructure, and startup support services.
• Bio-Minas BrasilsupportingStrategic or Co-development PartnerBio-Minas Brasil is a biotechnology ecosystem organization supporting the development of biotech companies and research initiatives in Minas Gerais, Brazil.
• Complexo Hospitalar São FranciscosupportingChannel Partner/ Reseller/ DistributorHealthcare institution partnership for providing Oncotag's genetic testing services to patients at their hospital facilities.
• IpsemgsupportingChannel Partner/ Reseller/ DistributorIpsemg (Instituto de Previdência dos Servidores do Estado de Minas Gerais) is a healthcare provider partnership for diagnostic testing services.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• Natera: Natera provides molecular testing across oncology (Signatera MRD) and reproductive health using bespoke assays — a broader incumbent whose Signatera tumor-informed MRD assay is the most direct global analog to Oncotag's recurrence-prediction OvarianTag product.

Direct peers

• Personalis: Personalis provides ultra-sensitive tumor profiling (NeXT Personal, ImmunoID) with AI-based molecular classifiers for cancer, broadly comparable to Oncotag's gene-expression-based AI assays for therapy selection and recurrence risk.
• Caris Life Sciences: Caris offers MI Profile / Caris Assure molecular profiling and AI-driven cancer diagnostics with companion-diagnostic positioning, making it a directly comparable precision oncology diagnostics peer for Oncotag's qRT-PCR + AI workflow.
• Veracyte: Veracyte is a genomic diagnostics company applying RNA-based gene-expression classifiers to oncology (Decipher, Afirma, Percepta), directly mirroring Oncotag's RNA-based, AI-classifier approach to cancer prognosis and therapy response.
• Tempus AI: Tempus combines multi-omics molecular profiling with proprietary AI models for cancer prognosis and therapy selection — a direct functional analog of Oncotag's gene-expression-plus-AI predictive oncology approach.
• Foundation Medicine: Foundation Medicine (now part of Roche) provides FoundationOne CDx comprehensive genomic profiling for solid tumors, the global benchmark for tumor molecular profiling directly overlapping with Oncotag's tumor genomic testing use case.
• Guardant Health: Guardant offers liquid-biopsy and tissue-based precision oncology tests (Guardant360, Reveal) using AI and NGS, overlapping directly with Oncotag's AI-driven prognostic and therapy-prediction panels for advanced cancers.
• Myriad Genetics: Myriad is a pioneer in germline and tumor molecular diagnostics (BRACAnalysis, myChoice HRD, Prolaris) directly comparable to Oncotag's gene-expression-based prognostic and predictive oncology tests, and is the field-defining reference for RNA/qPCR oncology assays.
• NeoGenomics: NeoGenomics operates a global oncology-focused clinical lab delivering molecular and genetic testing services to hospitals and oncologists — the same B2B diagnostic-services model Oncotag runs in Brazil at a much smaller scale.

Regional players

• DASA (Diagnósticos da América): DASA is the largest Brazilian diagnostics network offering molecular oncology, genomics, and pathology services — a direct regional comp for Oncotag's Brazilian tumor-genomics testing market and a likely channel partner or competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/oncotag
• LinkedInlinkedin.com/company/oncotag
• Instagraminstagram.com/oncotag

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Oncotag